Curis (FRA:CUS1) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS1 Curis Inc FRA:CUS1
55 GF Score
Price €3.93
GF Value €1.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:CUS1
55GF Score
Curis Inc FRA:CUS1
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Curis (FRA:CUS1) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €3.93 is trading 204.7% above its estimated GF Value™ of €1.29. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for FRA:CUS1:

  • Short Ratio:
  • GF Value™: €1.29 vs. price of €3.93 (204.7% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
55GF Score

Get the complete analysis for FRA:CUS1

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.93
Price
€1.29
GF Value